| |
| |
|
| Insider
Information: |
Schenkein David P |
| Relationship: |
Director |
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
168,823 |
|
|
Indirect Shares
|
417,826 |
|
|
| Direct
Value |
$5,035,310 |
|
|
|
Indirect Value
|
$13,780,226 |
|
|
| Total
Shares |
586,649 |
|
|
| Total
Value |
$18,815,536 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
3
|
|
Stock
price went up :
|
0
|
3
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
3.0
|
| Percentage
Gain/Loss : |
0.0%
|
 35.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Agios Pharmaceuticals Inc |
AGIO |
Director |
2024-02-27 |
122,854 |
2024-02-27 |
349,854 |
Premium* |
|
|
Foundation Medicine, Inc. |
FMI |
Director |
2016-06-16 |
23,326 |
2016-06-16 |
10,508 |
Premium* |
|
|
Bluebird Bio, Inc. |
BLUE |
|
2020-06-18 |
6,832 |
2014-12-19 |
0 |
Premium* |
|
|
Denali Therapeutics Inc. |
DNLI |
Director |
2023-06-01 |
15,529 |
2023-06-01 |
57,464 |
Premium* |
|
|
Regeneron Pharmaceuticals Inc |
REGN |
Director |
2024-01-02 |
282 |
2023-09-08 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
153 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 5 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AGIO |
Agios Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2018-06-01 |
4 |
OE |
$0.47 |
$6,280 |
D/D |
13,000 |
13,000 |
0 |
- |
|
| BLUE |
Bluebird Bio, Inc. |
Director |
– • – |
2018-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
4,176 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2018-09-05 |
4 |
OE |
$2.34 |
$249,028 |
D/D |
75,119 |
75,119 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2018-09-10 |
4 |
OE |
$31.64 |
$276,217 |
D/D |
8,730 |
83,849 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Chief Executive Officer |
• • – |
2018-11-08 |
4 |
GD |
$0.00 |
$0 |
I/I |
1,000 |
270,772 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2019-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,125 |
91,974 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2019-02-19 |
4 |
D |
$58.03 |
$143,392 |
D/D |
(2,471) |
89,503 |
0 |
- |
|
| BLUE |
Bluebird Bio, Inc. |
Director |
– • – |
2019-06-06 |
4 |
A |
$0.00 |
$0 |
D/D |
1,000 |
5,176 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2020-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,125 |
105,692 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2020-02-18 |
4 |
D |
$52.01 |
$131,793 |
D/D |
(2,534) |
103,158 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2020-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,775 |
105,933 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2020-02-24 |
4 |
D |
$48.66 |
$42,821 |
D/D |
(880) |
105,053 |
0 |
- |
|
| BLUE |
Bluebird Bio, Inc. |
|
– • – |
2020-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,656 |
6,832 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2020-11-04 |
4 |
AS |
$50.18 |
$501,830 |
D/D |
(10,000) |
65,000 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2020-11-10 |
4 |
AS |
$60.03 |
$600,310 |
D/D |
(10,000) |
55,000 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2020-11-12 |
4 |
AS |
$70.05 |
$2,101,590 |
D/D |
(30,000) |
25,000 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2020-12-21 |
4 |
AS |
$90.06 |
$2,251,555 |
D/D |
(25,000) |
0 |
0 |
% |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2020-12-21 |
4 |
AS |
$90.01 |
$450,027 |
I/I |
(5,000) |
26,232 |
0 |
% |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2021-02-16 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,540) |
110,638 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2021-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,125 |
113,178 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2021-02-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(821) |
112,591 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2021-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,774 |
113,412 |
0 |
- |
|
| AGIO |
Agios Pharmaceuticals Inc |
Director |
– • – |
2021-05-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,686 |
114,277 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,253 |
3,253 |
0 |
- |
|
| DNLI |
Denali Therapeutics Inc. |
Director |
– • – |
2021-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,074 |
5,327 |
0 |
- |
|
153 Records found
|
|
Page 5 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
